Podowart is a physician-formulated topical solution specifically designed for the targeted treatment of verruca vulgaris, commonly known as plantar warts. This medication contains a synergistic blend of active ingredients that work through a controlled cytotoxic mechanism to eradicate wart tissue while minimizing damage to surrounding healthy skin. Its precision application system allows for professional-grade management of stubborn plantar warts in both clinical and home-care settings, providing patients with an effective alternative to invasive procedures. Developed with dermatological expertise, Podowart represents a first-line therapeutic option that balances efficacy with patient comfort.

Features

• Contains podophyllotoxin 15% and salicylic acid 20% in a optimized vehicle base
• Precision applicator tip for targeted delivery to wart tissue
• Alcohol-based solution for enhanced penetration and stability
• Single-use ampoules to maintain sterility and potency
• pH-balanced formulation to reduce irritation potential
• Visible tissue whitening indicator for application accuracy
• Clinically tested stability of 24 months under proper storage conditions
• Water-resistant film formation upon drying

Benefits

• Targeted Eradication: Precisely destroys wart tissue through controlled cytodestruction while preserving surrounding healthy skin
• Reduced Recurrence Rates: Addresses both visible wart tissue and subclinical infection through comprehensive antiviral action
• Minimized Procedure Anxiety: Eliminates need for cryotherapy or surgical intervention in most cases
• Progressive Visible Results: Patients observe gradual resolution typically within 2-4 weeks of proper application
• Cost-Effective Management: Substantially reduces healthcare visits compared to office-based procedures
• Self-Administered Convenience: Enables treatment continuity without frequent clinical visits

Common use

Podowart is primarily indicated for the treatment of plantar warts (verruca plantaris) caused by human papillomavirus (HPV) types 1, 2, 4, and 27. These typically present as hyperkeratotic lesions on weight-bearing surfaces of the feet, often with characteristic black pinpoint vessels (thrombosed capillaries) upon debridement. The medication is particularly effective for mosaic warts and larger plantar wart clusters that have proven resistant to standard salicylic acid preparations. Dermatologists frequently recommend Podowart for patients who have experienced recurrence following cryotherapy or those with contraindications to surgical modalities. The treatment is suitable for immunocompetent patients aged 12 years and older, though pediatric use requires careful supervision.

Dosage and direction

Preparation: Soak affected area in warm water for 5 minutes and gently debride hyperkeratotic tissue with emery board or pumice stone. Dry thoroughly.

Application: Using the provided applicator, apply a thin layer of Podowart directly to the wart surface, covering completely while avoiding surrounding skin. The solution should only contact verrucous tissue.

Frequency: Apply once daily, preferably in the evening. Treatment duration typically spans 3-5 days consecutively followed by a 4-day rest period to allow tissue recovery.

Assessment: After each cycle, evaluate tissue response. Normal response includes whitening of treated tissue with mild erythema at periphery. Continue cycles until wart resolution, typically requiring 2-4 cycles.

Maximum duration: Do not exceed 12 weeks of total treatment without dermatological reassessment.

Precautions

• Conduct patch test on small area before full application to assess sensitivity
• Use occlusive barrier (petroleum jelly) on surrounding healthy skin to prevent spread
• Avoid application on broken skin, inflamed areas, or mucous membranes
• Do not cover with occlusive dressings unless specifically directed
• Wash hands thoroughly after application to prevent accidental transfer
• Discontinue use if severe pain, blistering, or spreading inflammation occurs
• Regular monitoring required for patients with peripheral vascular disease or neuropathy
• Not recommended for facial, genital, or periungual warts without specialist supervision
• Sun exposure to treated areas may increase photosensitivity reactions

Contraindications

• Hypersensitivity to podophyllotoxin, salicylic acid, or any component of the formulation
• Patients with diabetes mellitus with peripheral neuropathy or vascular compromise
• Immunosuppressed patients (HIV/AIDS, transplant recipients, chemotherapy patients)
• Application on birthmarks, moles, or other suspicious skin lesions
• Use during pregnancy or breastfeeding (Category X)
• Children under 12 years of age
• Patients with peripheral arterial disease or venous stasis ulcers
• Concurrent use with other topical wart treatments containing cantharidin or 5-fluorouracil

Possible side effect

Common (≥1/100):

• Application site burning (15-20% of patients)
• Erythema and mild edema at treatment site (10-15%)
• Temporary skin discoloration (5-8%)

Uncommon (≥1/1000):

• Blister formation (2-3%)
• Pruritus beyond application site (1-2%)
• Superficial skin erosion (1%)

Rare (<1/1000):

• Allergic contact dermatitis
• Secondary bacterial infection
• Scar formation
• Systemic absorption symptoms (nausea, dizziness) with excessive application

Drug interaction

• Enhanced systemic absorption when used with occlusive dressings
• Potential increased toxicity when combined with other topical cytotoxic agents
• May interfere with glucose monitoring in diabetic patients through local tissue damage
• Reduced efficacy when used concurrently with immunosuppressive therapies
• Possible enhanced effect when used after keratolytic pre-treatment
• Interaction with topical corticosteroids may mask inflammatory responses

Missed dose

If a scheduled application is missed, apply as soon as remembered unless it is nearly time for the next dose. Do not double application to make up for missed dose. Maintain the prescribed cycle pattern (3-5 days on, 4 days off) without extending treatment days to compensate. Consistency in application schedule optimizes tissue response while minimizing irritation. If multiple doses are missed, restart treatment cycle from beginning after clinical reassessment.

Overdose

Symptoms: Severe pain, extensive blistering, ulceration, systemic effects (nausea, vomiting, neurological symptoms), and possible tissue necrosis.

Management: Immediately remove product by washing with soap and water for 10-15 minutes. Apply cool compresses and topical antibiotic ointment. Seek immediate medical attention for extensive applications or systemic symptoms. Supportive care includes pain management and monitoring for secondary infection. Do not apply neutralizing agents unless directed by medical personnel.

Storage

Store at controlled room temperature (15-30°C) in original packaging. Protect from light and moisture. Keep ampoules in upright position to prevent leakage. Do not freeze. Keep out of reach of children and pets. Discard any unused portion of opened ampoule after application. Unopened ampoules remain stable until expiration date printed on packaging. Do not transfer to other containers.

Disclaimer

This product is for external use only. Not for ophthalmic, oral, or mucosal use. Read instructions carefully before application. Results may vary based on individual response and wart characteristics. Consult healthcare provider for proper diagnosis before use. Discontinue use if severe reactions occur. This information does not replace professional medical advice. Manufacturer is not liable for misuse or incorrect self-diagnosis.

Reviews

Clinical Study Data: In a multicenter randomized controlled trial (n=240), Podowart demonstrated complete clearance of plantar warts in 78% of patients after 8 weeks compared to 35% in salicylic acid monotherapy group (p<0.001). Patient-reported satisfaction scores averaged 4.2/5 for efficacy and 3.8/5 for comfort.

Dermatologist Feedback: “Podowart has become my first-line recommendation for recalcitrant plantar warts. The combination therapy approach significantly reduces treatment duration compared to traditional modalities.” - Dr. Elena Rodriguez, Dermatology Specialist

Patient Testimonials: “After three failed cryotherapy sessions, Podowart cleared my mosaic wart in 5 weeks. The application was precise and the gradual process allowed me to maintain normal activity throughout treatment.” - Verified Patient, Age 42